FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
26/07/2025
Voltar para busca
Dado oficial do USPTO
INTELLECTIVE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 42
Data de depósito
13/06/2023
Data de registro
07/01/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/01/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
CN
Examinador
WOLFE, YOUNG J
Unidade examinadora
N40
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "INTELLECTIVE" with the letters "LL" forming the legs of a person with outstretched arms.
Titulares e representantes
Titulares
Intellective Biologics (Suzhou) Co., Ltd.
NaTurtle AG
Representantes
Stephanie Goeller Holley & Menker
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancerautoimmune disordersinfectious diseases and cardiovascularpulmonary and neurological conditions; chemicals for use in industry and science; reagents for scientific apparatus for chemical or biological analyses being reagents for scientific and research use; protein in raw material form for scientific and medical research; biochemicals for in-vitro and in-vivo scientific use; biological preparations for use in industry and science; chemical preparations for use in industry; catalysts for chemical processes; diagnostic preparations for scientific use; diagnostic reagents for science or research use; stem cells for research purposes
Classe 5
Pharmaceutical products for treating cancerautoimmune disordersinfectious diseases and cardiovascularpulmonary and neurological conditions; medical preparations for the treatment of cancerautoimmune disordersinfectious diseases and cardiovascularpulmonary and neurological conditions; veterinary preparations for vaccinating livestock; disinfectants; preparations for destroying vermin; fungicides; herbicides; dietetic food and beverages adapted for medical use; dietetic pet foods and beverages for veterinary use; food for babies; food supplements; medical plastersmedical dressings; medicines for treating cancerautoimmune disordersinfectious diseases and cardiovascularpulmonary and neurological conditions
Classe 42
Research and development of new pharmaceutical productssuch as antibodiesantibody-drug conjugatesfusion proteins and other recombinant proteins; providing information with respect to medical and scientific research in the field of pharmaceutical products; pharmaceutical research and development services; consultation with respect to pharmaceutical research; medical research; scientific research services for medical purposes in the field of pharmaceuticals; biomedical research services; scientific and medical research and developmentresearch and development in the field of medical preparations; design and development of testing and analysis methods for new pharmaceutical product development; scientific research in the nature of conducting clinical trials for others; analysis and evaluation of newly developed pharmaceutical productssuch as antibodiesantibody-drug conjugatesfusion proteins and other recombinant proteins; analysis and evaluation of newly designed pharmaceutical productssuch as antibodiesantibody-drug conjugatesfusion proteins and other recombinant proteins; stem cell research services; scientific research services for medical purposes in the field of proteinsantibodiesmicroorganisms and cells; product research; providing medical and scientific research information in the field of pharmaceutical products and clinical trials; providing information on the results of clinical research trials for pharmaceutical products; consultation with respect to pharmaceutical research and development; providing integrated development of pharmaceutical productsresearch and development of pharmaceutical productsscientific research in the nature of conducting clinical trials and studies for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/07/2025
FIMP
FINAL DISPOSITION PROCESSED
05/07/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/04/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/03/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/02/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/02/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/01/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
07/01/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/11/2024
PUBO
PUBLISHED FOR OPPOSITION
19/11/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/11/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/10/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/09/2024
RFNT
REFUSAL PROCESSED BY IB
13/05/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
23/04/2024
RFRR
REFUSAL PROCESSED BY MPU
23/04/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/04/2024
CNRT
NON-FINAL ACTION WRITTEN
03/04/2024
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
30/03/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/03/2024
CNRT
NON-FINAL ACTION WRITTEN
04/03/2024
DOCK
ASSIGNED TO EXAMINER
04/03/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/12/2023
CHLD
CHANGE OF OWNER RECEIVED FROM IB
27/10/2023
MAFR
APPLICATION FILING RECEIPT MAILED
19/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/09/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
14/09/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace INTELLECTIVE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.